---
title: "CLENE INC C/WTS 30/12/2025 (TO PUR COM) | 8-K: FY2025 Q2 Revenue: USD 27 K"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/253050970.md"
datetime: "2025-08-14T12:44:59.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/253050970.md)
  - [en](https://longbridge.com/en/news/253050970.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/253050970.md)
generator: "portal-rs"
---

# CLENE INC C/WTS 30/12/2025 (TO PUR COM) | 8-K: FY2025 Q2 Revenue: USD 27 K

Revenue: As of FY2025 Q2, the actual value is USD 27 K.

EPS: As of FY2025 Q2, the actual value is USD -0.78.

### Financial Metrics Summary

#### Cash and Cash Equivalents

-   As of June 30, 2025, Clene Inc. reported cash and cash equivalents of $7.3 million, a decrease from $12.2 million as of December 31, 2024. The company expects that its resources, along with $1.9 million raised in equity and a $1.5 million increase in its convertible debt facility, will be sufficient to fund operations into the first quarter of 2026.

#### Research and Development Expenses

-   Research and development expenses were $3.5 million for the quarter ended June 30, 2025, compared to $4.2 million for the same period in 2024. The decrease was primarily due to reduced personnel expenses and stock-based compensation, offset by increased expenses related to the ALS clinical programs.

#### General and Administrative Expenses

-   General and administrative expenses were $2.4 million for the quarter ended June 30, 2025, down from $3.3 million for the same period in 2024. This decrease was mainly due to reduced personnel expenses, stock-based compensation, and legal fees, partially offset by increased finance and accounting fees.

#### Net Loss

-   Clene reported a net loss of $7.4 million, or $0.78 per share, for the quarter ended June 30, 2025, compared to a net loss of $6.8 million, or $1.06 per share, for the same period in 2024.

#### Total Other Expense

-   Total other expense was $1.6 million for the quarter ended June 30, 2025, compared to total other income of $0.6 million for the same period in 2024. This change was primarily due to non-cash losses on derivative liabilities and common stock warrant liabilities, and decreased interest income.

### Outlook / Guidance

-   Clene plans to analyze neurofilament light data from its NIH-sponsored Early Access Protocol in the fourth quarter of 2025 and expects to submit a New Drug Application for CNM-Au8 in ALS by the end of 2025. The company anticipates that its current resources will fund operations into the first quarter of 2026.

### Related Stocks

- [CLNNW.US](https://longbridge.com/en/quote/CLNNW.US.md)

## Related News & Research

- [3,759 Shares in Ferrari N.V. $RACE Acquired by X Square Capital LLC](https://longbridge.com/en/news/296700358.md)
- [Powerful Growth, Multiple Endorsements Bode Well for Oracle Stock](https://longbridge.com/en/news/296686709.md)
- [Korea Investment CORP Increases Stock Position in L3Harris Technologies Inc $LHX](https://longbridge.com/en/news/296698330.md)
- [Johnson & Johnson $JNJ Position Reduced by Oppenheimer Asset Management Inc.](https://longbridge.com/en/news/296697035.md)
- [Danske Bank A S Invests $252.05 Million in Bank of America Corporation $BAC](https://longbridge.com/en/news/296695181.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**